Table 6. Percentages and total number of different CD4 T subsets gated according to the CCR6, CCR4 and CCR10 staining.
Patients were grouped according to the kind of therapy.
| No BT (n = 4) | Anti-TNFα BT (n = 33) | Anti-CD20 BT (n = 5) | Anti-IL6R/Ig-CTLA4 BT (n = 7) | |||||
|---|---|---|---|---|---|---|---|---|
| Mean ± SD | CI (95%) | Mean ± SD | CI (95%) | Mean ± SD | CI (95%) | Mean ± SD | CI (95%) | |
| % lymphocytes | 24.98 ± 5.08* | 16.89–33.06 | 27.76 ± 10.52* # | 24.02–31.49 | 19.29 ± 6.2 | 11.6–26.98 | 14.43 ± 6.8* # | 8.14–20.71 |
| % lymphocytes CD4 + CCR6 + | 1.56 ± 0.87 | 0.16–2.95 | 2.21 ± 1.29* | 1.76–2.67 | 1.93 ± 1.61 | (-)0.06–3.93 | 0.85 ± 0.38* | 0.5–1.2 |
| % CCR10 + CCR4 + in CD4 + CCR6 + | 3.15 ± 1.68 | (-)1.01–7.31 | 4.96 ± 4.39 | 3.35–6.57 | 4.94 ± 1.14 | 3.12–6.77 | 4.81 ± 1.53 | 3.2–6.41 |
| % CCR10 + CCR4 - in CD4 + CCR6 + | 3.77 ± 3.11* ¢ | (-)3.95–11.49 | 9.5 ± 12.18¢ | 5.03–13.97 | 10.62 ± 3.53* | 5–16.25 | 22.57 ± 18.76 | 2.87–42.26 |
| Number of lymphocytes (x 10 9 cel L -1 ) | 2.12 ± 0.94 | 1.7–2.53 | 2.73 ± 0.98 | 2.47–2.98 | 2.07 ± 0.8 | 1.6–2.53 | 2.32 ± 0.54 | 2.01–2.62 |
| Number of lymphocytes CD4 + CCR6 + (x 10 9 cel L -1 ) | 0.16 ± 0.14 | (-)0.07–0.38 | 0.23 ± 0.15* | 0.18–0.28 | 0.2 ± 0.17 | (-)0.01–0.40 | 0.15 ± 0.05* | 0.11–0.2 |
| Number of CCR10 + CCR4 + in CD4 + CCR6 + (x 10 6 cel L -1 ) | 2.48 ± 1.64* | (-)1.59–6.55 | 10.82 ± 13.5 | 5.87–15.78 | 5.95 ± 2.03 | 2.71–9.19 | 6.73 ± 2.48* | 4.12–9.33 |
| Number of CCR10 + CCR4 - in CD4 + CCR6 + (x 10 6 cel L -1 ) | 2.14 ± 0.69* | 0.42–0.3.8 | 18.34 ± 17.85 | 11.79–24.88 | 12.97 ± 4.99* | 5.02–20.92 | 32.73 ± 27.81* | 3.55–61.92 |
n = number of samples; CI = confidence interval; SD = standard deviation; BT = biological therapy
* Values significantly different among groups (not specified) at p < 0.05 (Student´s t test)
# Values significantly different among groups at p < 0.05 (Scheffé´s test)
¢ Values significantly different among groups at p < 0.05 (Dunnett´s C test)